Non-small cell lung cancer with EGFR alterations
Clinical research at Vestre Viken HF includes treatment of EGFR-mutated non-small cell lung cancer, with interest in first-line targeted therapy and associated biological sampling.
- Osimertinib
- Objective response rate
- Biological samples
The focus reflects active involvement in molecularly defined lung cancer care in the advanced oncology setting.
KRAS G12C-mutated non-small cell lung cancer
The sponsor also studies KRAS G12C-mutated non-small cell lung cancer, with attention to patients who have additional medical conditions and require tailored cancer treatment approaches.
- Sotorasib
- Tumour size reduction
- Comorbidities
This area places emphasis on targeted therapy for genetically defined lung cancer populations.
Advanced and metastatic non-small cell lung cancer
Research activity extends to advanced and metastatic non-small cell lung cancer, including evaluation of PD-1 and PD-L1 inhibitor-based treatment strategies.
- PD-1/PD-L1 inhibitors
- UV1 vaccination
- Stage IIIB/IIIC
- Stage IV NSCLC
These studies address immunotherapy-focused care for patients with more extensive lung cancer disease.
Perioperative anaesthesia and opioid effects
Beyond oncology, the sponsor funds research on the affective effects of commonly used perioperative opioids in the surgical setting, with relevance to general anaesthesia and day surgery care.
- Morphine
- Oxycodone
- Fentanyl
- Placebo-controlled trial
The clinical interest includes pain management and patient-reported affective responses around surgery.
